Genomic Track

26th November – 09:00 – 10:15 – Opening Session
Education Track

Perspectives on Genomics

Genomics has been a game-changer for clinical and translational research over the past decade, and has improved success in drug discovery and development. Major genomics programmes are also recognised as having stimulated significant economic return. The economic impact of the Human Genome Project in the USA has been calculated as $796 billion from a $3.8 billion investment, a return on investment of 141:1.

This session will set out an overview from a regulatory, political, patient and industry perspective the advancements that can take through the following areas:

  • Improving Treatment Selection in Cancer
  • Maximising Success of Diagnosis in Rare Diseases
  • The Power of a Diagnosis
  • Tracking a Disease Outbreak

Chair

Tonu Esku

Tonu Esko

Deputy Director of Research, Estonian Biobank, Estonian Genome Center, University of Tartu, Estonia

Panel

Dennis Horgan

Denis Horgan

Executive Director, European Alliance for Personalised Medicine

Public responses to genomics – global views

Anna Middleton

Anna Middleton

Head of Society and Ethics Research Wellcome Genome Campus, Cambridge, UK

Draga Toncheva

Draga Toncheva

President of the Bulgarian Society for Genetics and Human Genomics

Sergio Abrignani

Sergio Abrignani

Scientific Director of the National Institute of Molecular Genetics (INGM – IstitutoNazionale di GeneticaMolecolare) of Milan